Literature DB >> 28522933

Management of testicular cancer: NYU case of the month, March 2017.

James S Wysock1.   

Abstract

Entities:  

Year:  2017        PMID： 28522933      PMCID： PMC5434839          DOI： 10.3909/riu0757

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  25 in total

1.  Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection.

Authors:  B P Hermans; C J Sweeney; R S Foster; L E Einhorn; J P Donohue
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

Review 2.  Sequelae of treatment in long-term survivors of testis cancer.

Authors:  Robert Abouassaly; Sophie D Fossa; Aleksander Giwercman; Christian Kollmannsberger; Robert J Motzer; Hans-Joachim Schmoll; Cora N Sternberg
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

3.  Noncancer causes of death in survivors of testicular cancer.

Authors:  Sophie D Fosså; Ethel Gilbert; Graça M Dores; Jinbo Chen; Katherine A McGlynn; Sara Schonfeld; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Heikki Joensuu; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Randi Cohen; Eero Pukkala; Lois B Travis
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

4.  Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer.

Authors:  Stephen B Williams; Clayton S Lau; David Y Josephson
Journal:  Eur Urol       Date:  2011-03-21       Impact factor: 20.096

5.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

Authors:  Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

8.  Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

Authors:  Hege S Haugnes; George J Bosl; Hink Boer; Jourik A Gietema; Marianne Brydøy; Jan Oldenburg; Alv A Dahl; Roy M Bremnes; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

9.  Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy.

Authors:  C Kollmannsberger; C Moore; K N Chi; N Murray; S Daneshmand; M Gleave; B Hayes-Lattin; C R Nichols
Journal:  Ann Oncol       Date:  2009-10-29       Impact factor: 32.976

10.  Renal function related to different treatment modalities for malignant germ cell tumours.

Authors:  N Aass; S D Fosså; M Aas; M W Lindegaard
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.